Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Date:11/30/2009

AMSTERDAM, November 30 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

The study is currently open for enrollment in centers in Europe and Canada and is designed to serve as a registration trial for European approval.

"We are very pleased to initiate the registration study following excellent clinical results from the phase I/II study with ATIR(TM)." says Dr. Manja Bouman, CEO of Kiadis Pharma. "ATIR(TM) has shown a low TRM at one year post transplantation and a high overall survival in a patient population with no standard treatment options left. As an orphan product addressing a high unmet need, we aim to take advantage of a fast development path for ATIR(TM)."

"As the pioneer of ATIR(TM) I am very excited about this next major development milestone, a multinational registration study" says Dr. Denis Claude Roy of the University of Montreal. "I am a strong believer that ATIR(TM) will open up a whole new treatment field for a very large patient group which currently has no treatment options left."

About ATIR(TM)

ATIR(TM), a donor lymphocyte preparation depleted of alloreactive T-cells, is under development to reduce transplant related mortality (TRM) following an allogeneic hematopoietic stem cell transplantation (HSCT). ATIR(TM) is designed to provide early immune reconstitution to fight infections and remaining tumor cells (by eliminating the use of prophylactic immune suppressants) while preventing acute severe (Grade III
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Global polyvinyl chloride (PVC) demand registered a ... 2008-2009, especially in North America and Europe. However, the ... to a growing trend. , The largest chunk of ... construction segment. In 2013, the key PVC application spheres ... rigid film. Moreover, the PVC was consumed in the ...
(Date:10/30/2014)... October 30, 2014 SoundConnect ... provider, offers Office 365 end users the key ... complete phone system by adding voice enablement and ... includes Lync Online, a communication tool that includes ... With hosted voice, O365 becomes a comprehensive unified ...
(Date:10/30/2014)... 2014 Spartan Bioscience announced today that ... System . It detects CYP2C19 genetic mutations in less ... The Spartan RX CYP2C19 System is the first near-patient ... in Canada. Due to the system’s ease of use, ... by healthcare professionals such as doctors, nurses, pharmacists, and ...
(Date:10/30/2014)... Ras Al Khaimah, UAE (PRWEB) October 30, 2014 ... the appointment of Dr. James A. Manganello, Chairman of the ... (NSCEC) of The Bahamas. The appointment was made by ... The Bahamas on September 24th, 2014. , More ... Cell Therapy and Research Bill , Prime Minister Perry Christie ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 2SoundConnect Launches Voice Enablement and Hybrid Audio Conferencing for Office 365 3Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3
... (EMBL) discovered a new way to make use of drugs, ... how similar the side effects of different drugs are and ... molecule. The study, published in Science this week, ... often share target proteins, modes of action and unpleasant side ...
... ATRC ), a medical device company and a leader ... the second,quarter ended June 30, 2008 on Tuesday, August 5, ... a.m. ET on Tuesday,August 5, 2008 to discuss second quarter ... be available online from the investor relations,page of AtriCure,s corporate ...
... increased 38% to $42.3 million ... income rose 30% to $14.2 million, SHANGHAI, ... Board: CHBT) ("China-Biotics", "the,Company"), a leading Chinese firm ... of probiotics products,today announced its financial results for ...
Cached Biology Technology:Teaching old drugs new tricks 2AtriCure Announces Web Cast and Conference Call of Second Quarter 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 13
(Date:10/31/2014)... a new test that can distinguish between birds that ... influenza virus or "bird flu" with those that have ... in the fight against this often fatal strain of ... of South East Asia, particularly Indonesia and Vietnam. , ... to humans and the threat of a pandemic if ...
(Date:10/31/2014)... , Oct. 30, 2014  HITLAB SM ... pleased to announce its inaugural HITLAB Innovators Summit ... University,s Low Library. HITLAB will partner with the ... Wellness, Blueprint Health, ProtoHack, Columbia Business School Alumni ... and Columbia Industrial Engineering and Operations Research, bringing ...
(Date:10/30/2014)... a $1.04 million grant from the U.S. Army ... osteoarthritis using a patient,s own stem cells, spurred ... polymers., Liping Tang, a bioengineering professor and interim ... is primarily focused on helping soldiers who are ... if we inject microscaffolding that we,ve developed into ...
Breaking Biology News(10 mins):New step towards eradication of H5N1 bird flu 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2
... medication robbed Elma Phifer of her vision two decades ago ... reduced the ability of her eyes to soothe their damaged ... family and friends to help her do many of the ... twenty years and several life milestones later, Elma is able ...
... share a genetic profile that appears to be unique ... researchers at Cincinnati Children's Hospital Medical Center. The discovery ... specifically tailored to children who suffer from the severest ... Feb. 10 issue of the Journal of Allergy and ...
... throw a wrench in the transmissions of several speed demons ... Medicine in St. Louis and Harvard University have identified a ... slow cell invasion by malaria and other parasites known as ... March 15 issue of Proceedings of the National Academy of ...
Cached Biology News:Artifical cornea lets woman blind 20 years see 2Artifical cornea lets woman blind 20 years see 3Artifical cornea lets woman blind 20 years see 4Asthma gene clusters identified 2Asthma gene clusters identified 3Protein offers way to stop microscopic parasites in their tracks 2Protein offers way to stop microscopic parasites in their tracks 3
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
HOXC11 Antibody...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: